Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RAS family consists of small GTPases encoded by three main human genes (HRAS, NRAS, KRAS producing four isoforms: HRAS, NRAS, KRAS4A, KRAS4B) that function as molecular switches cycling between GDP-bound inactive and GTP-bound active states to regulate key signaling pathways. They share a conserved G-domain for GTP binding/hydrolysis and effector interactions (e.g., RAF kinases via switch I/II regions), with a hypervariable C-terminal region for membrane anchoring. RAS activates downstream cascades like RAF-MEK-ERK for cell proliferation and survival, and mutations locking GTP-bound state drive ~30% of cancers. Structures reveal β-sheet/α-helix folds akin to EF-Tu, with post-translational modifications (prenylation, acetylation) critical for function
Direct binding to switch pockets of mutant KRAS to lock inactive conformation, Inhibition of GTP binding, GAP-mediated GTP hydrolysis enhancement, RAF kinase dimerization blockade, Farnesylation blockade for membrane localization
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAS family (RAS).